The results showed that SFXN1 expression was significantly higher in patients with locally advanced stage (P < 0.0001), lymph node metastasis (P < 0.0001), and larger tumor size (P = 0.0123) than in patients with early-stage disease, no lymph node metastasis, and T1 stage disease (Fig. 10E-G). This evidence concerns the gene SFXN1 and metastatic malignant neoplasm in the lymph nodes.